With data gathered from the United Kingdom’s General Practice Research Database from 1986-2006, researchers were able to examine the impact of using biophosphonate after total joint arthroplasty. The report didn’t include patients who had a history of hip fracture or rheumatoid arthritis or patients under the age of 40.
There were 41,995 patients included in the study and 1,912 were biophosphonate users. Biophosphonate users were patients with at least six prescriptions of biophosphonates or patients who underwent at least six months of prescribed biophosphonate treatment with more than 80 percent adherence before revision surgery. Biophosphonate users reported a lower revision rate at five years than non-users and implant survival was significantly longer in the biophosphonate group.
The biophosphonate group also reported almost twofold increase in time between initial and revision knee arthroplasty compared with the non-user group.
Related Articles on Orthopedic Devices:
New Hip Implants Don’t Show Improvement Over Old Models
Zimmer Acquires Xtra Fix External Fixation System
Wright Medical Group to Focus on Extremities Market After Sales Decrease of 3% in 3Q
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
